Global Antibiotic Resistance Market

Antibiotic Resistance Comprehensive Study by Disease (Complicated Urinary Tract Infection {cUTI}, Complicated Intra-Abdominal Infections {cIAI}, Blood Stream Infections {BSI}, Clostridium difficile infections {CDI}, Acute Bacterial Skin and Skin Structure Infections {ABSSSI}, Hospital Acquired Bacterial Pneumonia/Ventilator {HABP/VABP}, Community Acquired Bacterial Pneumonia {CABP}), Pathogen (Acinetobacter baumannii {Carbapenem-Resistant and ESBL-producing}, Pseudomonas aeruginosa {Carbapenem-Resistant}, Staphylococcus Aureus {Methicillin-Resistant}, E. coli/K. pneumoniae {Carbapenem-Resistant}, Streptococcus pneumoniae {Penicillin-Non-Susceptible}, Clostridium difficile {Cephalosporin-Resistant, Tetracycline-Resistant}, Enterococcus faecium {Vancomycin-Resistant}, Haemophilus Influenzae {Ampicillin-Resistant}), Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination therapies, Others) Players and Region - Global Market Outlook to 2030

Antibiotic Resistance Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.18%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Antibiotic Resistance
Antibiotics are the antimicrobial substance that is used to fight against the bacterial infection. Antibiotics are also used to cure several conditions including strep throat, urinary tract infections, sinus infections, ear infections, pneumonia, and skin infections, among others. The antibiotics are classified on the basis of the spectrum of activity, chemical structures, and mode of action. The ability to resist bacterial infection is termed antibiotic resistance. Bacterial infection has become a major concern worldwide. Therefore, major pharmaceutical companies are involved in the development of broad-spectrum antibiotics.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR6.18%


Manufacturers focus on the development of new antibiotics or alternative therapies to treat antibiotic-resistant infections. This may involve investing in research and development, as well as partnering with academic institutions or other companies to bring new treatments to market. Another strategy is to focus on infection prevention and control measures, such as hand hygiene and environmental cleaning, to reduce the spread of antibiotic-resistant infections. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Antibiotic Resistance market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer Inc. (United States), Novartis AG (Switzerland), Allergan (Ireland), Melinta Therapeutics (United States), Novartis AG (Switzerland), GlaxoSmithKline PLC (United Kingdom), Merck & Co. Inc. (United States), Sanofi SA (France), Johnson & Johnson (United States) and Roche (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Shionogi (Japan), Lupin (India), Sun Pharma (India), Teva (Israel) and Mylan (United States).

Segmentation Overview
AMA Research has segmented the market of Global Antibiotic Resistance market by and Region.



On the basis of geography, the market of Antibiotic Resistance has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by Disease, the sub-segment i.e. Complicated Urinary Tract Infection {cUTI} will boost the Antibiotic Resistance market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Pathogen , the sub-segment i.e. Acinetobacter baumannii {Carbapenem-Resistant and ESBL-producing} will boost the Antibiotic Resistance market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Oxazolidinones will boost the Antibiotic Resistance market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Latest Technological Advancements in Biotechnology Field

Market Growth Drivers:
Increase in Global Initiatives to Control Drug-Resistance, Growing Demand for Generic Drugs, High Burden of Antibiotic-Resistant Infections and The emergence of Multi-Drug Resistant Pathogens

Challenges:
Increasing Resistance Against Antibiotics Associated With Product Recalls and Limited Number of Manufacturers in the Field Of Antibiotic Resistance

Restraints:
The High-Cost Associated With the Treatment

Opportunities:
The Policies for the Development of New Therapies for Growing Burden and Severity of Antibiotic-Resistant Infections

Market Leaders and their expansionary development strategies
On 3 Oct 2018, Novartis, a leading pharmaceutical company announced an equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates that are part of the Novartis Infectious Diseases portfolio that have the potential to address the need for new agents to treat antibiotic-resistant Gram-negative infections.
On 11 May 2018, Melinta Therapeutics, Inc., announced the launch of a new antibiotic stewardship program designed to address the growing threat of antimicrobial resistance (AMR). and On 21 April 2017, Pfizer Inc. announced the launch of the company’s Antimicrobial Testing Leadership and Surveillance website which is designed to provide physicians and the global health community with easy access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns across more than sixty countries.
In the European Union, the European Centre for Disease Prevention and Control (ECDC) is responsible for monitoring and preventing the spread of antibiotic-resistant infections. The European Medicines Agency (EMA) regulates the approval of antibiotics and monitors their safety and effectiveness.

Key Target Audience
Antibiotic Resistance Drug Manufacturers, Antibiotic Resistance Drug Distributor/Suppliers, Government Agencies, Research Institute, Market Research Firms and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Disease
  • Complicated Urinary Tract Infection {cUTI}
  • Complicated Intra-Abdominal Infections {cIAI}
  • Blood Stream Infections {BSI}
  • Clostridium difficile infections {CDI}
  • Acute Bacterial Skin and Skin Structure Infections {ABSSSI}
  • Hospital Acquired Bacterial Pneumonia/Ventilator {HABP/VABP}
  • Community Acquired Bacterial Pneumonia {CABP}

By Pathogen
  • Acinetobacter baumannii {Carbapenem-Resistant and ESBL-producing}
  • Pseudomonas aeruginosa {Carbapenem-Resistant}
  • Staphylococcus Aureus {Methicillin-Resistant}
  • E. coli/K. pneumoniae {Carbapenem-Resistant}
  • Streptococcus pneumoniae {Penicillin-Non-Susceptible}
  • Clostridium difficile {Cephalosporin-Resistant, Tetracycline-Resistant}
  • Enterococcus faecium {Vancomycin-Resistant}
  • Haemophilus Influenzae {Ampicillin-Resistant}

By Drug Class
  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Cephalosporins
  • Combination therapies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Global Initiatives to Control Drug-Resistance
      • 3.2.2. Growing Demand for Generic Drugs
      • 3.2.3. High Burden of Antibiotic-Resistant Infections
      • 3.2.4. The emergence of Multi-Drug Resistant Pathogens
    • 3.3. Market Challenges
      • 3.3.1. Increasing Resistance Against Antibiotics Associated With Product Recalls
      • 3.3.2. Limited Number of Manufacturers in the Field Of Antibiotic Resistance
    • 3.4. Market Trends
      • 3.4.1. Latest Technological Advancements in Biotechnology Field
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antibiotic Resistance, by Disease, Pathogen , Drug Class and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Antibiotic Resistance (Value)
      • 5.2.1. Global Antibiotic Resistance by: Disease (Value)
        • 5.2.1.1. Complicated Urinary Tract Infection {cUTI}
        • 5.2.1.2. Complicated Intra-Abdominal Infections {cIAI}
        • 5.2.1.3. Blood Stream Infections {BSI}
        • 5.2.1.4. Clostridium difficile infections {CDI}
        • 5.2.1.5. Acute Bacterial Skin and Skin Structure Infections {ABSSSI}
        • 5.2.1.6. Hospital Acquired Bacterial Pneumonia/Ventilator {HABP/VABP}
        • 5.2.1.7. Community Acquired Bacterial Pneumonia {CABP}
      • 5.2.2. Global Antibiotic Resistance by: Drug Class (Value)
        • 5.2.2.1. Oxazolidinones
        • 5.2.2.2. Lipoglycopeptides
        • 5.2.2.3. Tetracyclines
        • 5.2.2.4. Cephalosporins
        • 5.2.2.5. Combination therapies
        • 5.2.2.6. Others
      • 5.2.3. Global Antibiotic Resistance Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Antibiotic Resistance: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergan (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Melinta Therapeutics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co. Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi SA (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Johnson & Johnson (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Roche (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antibiotic Resistance Sale, by Disease, Pathogen , Drug Class and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Antibiotic Resistance (Value)
      • 7.2.1. Global Antibiotic Resistance by: Disease (Value)
        • 7.2.1.1. Complicated Urinary Tract Infection {cUTI}
        • 7.2.1.2. Complicated Intra-Abdominal Infections {cIAI}
        • 7.2.1.3. Blood Stream Infections {BSI}
        • 7.2.1.4. Clostridium difficile infections {CDI}
        • 7.2.1.5. Acute Bacterial Skin and Skin Structure Infections {ABSSSI}
        • 7.2.1.6. Hospital Acquired Bacterial Pneumonia/Ventilator {HABP/VABP}
        • 7.2.1.7. Community Acquired Bacterial Pneumonia {CABP}
      • 7.2.2. Global Antibiotic Resistance by: Drug Class (Value)
        • 7.2.2.1. Oxazolidinones
        • 7.2.2.2. Lipoglycopeptides
        • 7.2.2.3. Tetracyclines
        • 7.2.2.4. Cephalosporins
        • 7.2.2.5. Combination therapies
        • 7.2.2.6. Others
      • 7.2.3. Global Antibiotic Resistance Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antibiotic Resistance: by Disease(USD Million)
  • Table 2. Antibiotic Resistance Complicated Urinary Tract Infection {cUTI} , by Region USD Million (2018-2023)
  • Table 3. Antibiotic Resistance Complicated Intra-Abdominal Infections {cIAI} , by Region USD Million (2018-2023)
  • Table 4. Antibiotic Resistance Blood Stream Infections {BSI} , by Region USD Million (2018-2023)
  • Table 5. Antibiotic Resistance Clostridium difficile infections {CDI} , by Region USD Million (2018-2023)
  • Table 6. Antibiotic Resistance Acute Bacterial Skin and Skin Structure Infections {ABSSSI} , by Region USD Million (2018-2023)
  • Table 7. Antibiotic Resistance Hospital Acquired Bacterial Pneumonia/Ventilator {HABP/VABP} , by Region USD Million (2018-2023)
  • Table 8. Antibiotic Resistance Community Acquired Bacterial Pneumonia {CABP} , by Region USD Million (2018-2023)
  • Table 9. Antibiotic Resistance: by Drug Class(USD Million)
  • Table 10. Antibiotic Resistance Oxazolidinones , by Region USD Million (2018-2023)
  • Table 11. Antibiotic Resistance Lipoglycopeptides , by Region USD Million (2018-2023)
  • Table 12. Antibiotic Resistance Tetracyclines , by Region USD Million (2018-2023)
  • Table 13. Antibiotic Resistance Cephalosporins , by Region USD Million (2018-2023)
  • Table 14. Antibiotic Resistance Combination therapies , by Region USD Million (2018-2023)
  • Table 15. Antibiotic Resistance Others , by Region USD Million (2018-2023)
  • Table 16. South America Antibiotic Resistance, by Country USD Million (2018-2023)
  • Table 17. South America Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 18. South America Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 19. South America Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 20. Brazil Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 21. Brazil Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 22. Brazil Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 23. Argentina Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 24. Argentina Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 25. Argentina Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 26. Rest of South America Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 27. Rest of South America Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 28. Rest of South America Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 29. Asia Pacific Antibiotic Resistance, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 31. Asia Pacific Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 32. Asia Pacific Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 33. China Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 34. China Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 35. China Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 36. Japan Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 37. Japan Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 38. Japan Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 39. India Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 40. India Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 41. India Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 42. South Korea Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 43. South Korea Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 44. South Korea Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 45. Taiwan Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 46. Taiwan Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 47. Taiwan Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 48. Australia Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 49. Australia Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 50. Australia Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 54. Europe Antibiotic Resistance, by Country USD Million (2018-2023)
  • Table 55. Europe Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 56. Europe Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 57. Europe Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 58. Germany Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 59. Germany Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 60. Germany Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 61. France Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 62. France Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 63. France Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 64. Italy Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 65. Italy Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 66. Italy Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 67. United Kingdom Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 68. United Kingdom Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 69. United Kingdom Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 70. Netherlands Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 71. Netherlands Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 72. Netherlands Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 73. Rest of Europe Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 74. Rest of Europe Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 75. Rest of Europe Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 76. MEA Antibiotic Resistance, by Country USD Million (2018-2023)
  • Table 77. MEA Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 78. MEA Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 79. MEA Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 80. Middle East Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 81. Middle East Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 82. Middle East Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 83. Africa Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 84. Africa Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 85. Africa Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 86. North America Antibiotic Resistance, by Country USD Million (2018-2023)
  • Table 87. North America Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 88. North America Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 89. North America Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 90. United States Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 91. United States Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 92. United States Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 93. Canada Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 94. Canada Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 95. Canada Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 96. Mexico Antibiotic Resistance, by Disease USD Million (2018-2023)
  • Table 97. Mexico Antibiotic Resistance, by Pathogen USD Million (2018-2023)
  • Table 98. Mexico Antibiotic Resistance, by Drug Class USD Million (2018-2023)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Antibiotic Resistance: by Disease(USD Million)
  • Table 110. Antibiotic Resistance Complicated Urinary Tract Infection {cUTI} , by Region USD Million (2025-2030)
  • Table 111. Antibiotic Resistance Complicated Intra-Abdominal Infections {cIAI} , by Region USD Million (2025-2030)
  • Table 112. Antibiotic Resistance Blood Stream Infections {BSI} , by Region USD Million (2025-2030)
  • Table 113. Antibiotic Resistance Clostridium difficile infections {CDI} , by Region USD Million (2025-2030)
  • Table 114. Antibiotic Resistance Acute Bacterial Skin and Skin Structure Infections {ABSSSI} , by Region USD Million (2025-2030)
  • Table 115. Antibiotic Resistance Hospital Acquired Bacterial Pneumonia/Ventilator {HABP/VABP} , by Region USD Million (2025-2030)
  • Table 116. Antibiotic Resistance Community Acquired Bacterial Pneumonia {CABP} , by Region USD Million (2025-2030)
  • Table 117. Antibiotic Resistance: by Drug Class(USD Million)
  • Table 118. Antibiotic Resistance Oxazolidinones , by Region USD Million (2025-2030)
  • Table 119. Antibiotic Resistance Lipoglycopeptides , by Region USD Million (2025-2030)
  • Table 120. Antibiotic Resistance Tetracyclines , by Region USD Million (2025-2030)
  • Table 121. Antibiotic Resistance Cephalosporins , by Region USD Million (2025-2030)
  • Table 122. Antibiotic Resistance Combination therapies , by Region USD Million (2025-2030)
  • Table 123. Antibiotic Resistance Others , by Region USD Million (2025-2030)
  • Table 124. South America Antibiotic Resistance, by Country USD Million (2025-2030)
  • Table 125. South America Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 126. South America Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 127. South America Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 128. Brazil Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 129. Brazil Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 130. Brazil Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 131. Argentina Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 132. Argentina Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 133. Argentina Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 134. Rest of South America Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 135. Rest of South America Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 136. Rest of South America Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 137. Asia Pacific Antibiotic Resistance, by Country USD Million (2025-2030)
  • Table 138. Asia Pacific Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 139. Asia Pacific Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 140. Asia Pacific Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 141. China Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 142. China Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 143. China Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 144. Japan Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 145. Japan Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 146. Japan Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 147. India Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 148. India Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 149. India Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 150. South Korea Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 151. South Korea Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 152. South Korea Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 153. Taiwan Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 154. Taiwan Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 155. Taiwan Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 156. Australia Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 157. Australia Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 158. Australia Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 159. Rest of Asia-Pacific Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 160. Rest of Asia-Pacific Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 162. Europe Antibiotic Resistance, by Country USD Million (2025-2030)
  • Table 163. Europe Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 164. Europe Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 165. Europe Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 166. Germany Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 167. Germany Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 168. Germany Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 169. France Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 170. France Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 171. France Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 172. Italy Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 173. Italy Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 174. Italy Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 175. United Kingdom Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 176. United Kingdom Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 177. United Kingdom Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 178. Netherlands Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 179. Netherlands Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 180. Netherlands Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 181. Rest of Europe Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 182. Rest of Europe Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 183. Rest of Europe Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 184. MEA Antibiotic Resistance, by Country USD Million (2025-2030)
  • Table 185. MEA Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 186. MEA Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 187. MEA Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 188. Middle East Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 189. Middle East Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 190. Middle East Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 191. Africa Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 192. Africa Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 193. Africa Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 194. North America Antibiotic Resistance, by Country USD Million (2025-2030)
  • Table 195. North America Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 196. North America Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 197. North America Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 198. United States Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 199. United States Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 200. United States Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 201. Canada Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 202. Canada Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 203. Canada Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 204. Mexico Antibiotic Resistance, by Disease USD Million (2025-2030)
  • Table 205. Mexico Antibiotic Resistance, by Pathogen USD Million (2025-2030)
  • Table 206. Mexico Antibiotic Resistance, by Drug Class USD Million (2025-2030)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antibiotic Resistance: by Disease USD Million (2018-2023)
  • Figure 5. Global Antibiotic Resistance: by Drug Class USD Million (2018-2023)
  • Figure 6. South America Antibiotic Resistance Share (%), by Country
  • Figure 7. Asia Pacific Antibiotic Resistance Share (%), by Country
  • Figure 8. Europe Antibiotic Resistance Share (%), by Country
  • Figure 9. MEA Antibiotic Resistance Share (%), by Country
  • Figure 10. North America Antibiotic Resistance Share (%), by Country
  • Figure 11. Global Antibiotic Resistance share by Players 2023 (%)
  • Figure 12. Global Antibiotic Resistance share by Players (Top 3) 2023(%)
  • Figure 13. Global Antibiotic Resistance share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 17. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 19. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Allergan (Ireland) Revenue: by Geography 2023
  • Figure 21. Melinta Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 22. Melinta Therapeutics (United States) Revenue: by Geography 2023
  • Figure 23. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 25. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck & Co. Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Sanofi SA (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi SA (France) Revenue: by Geography 2023
  • Figure 31. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 33. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Roche (Switzerland) Revenue: by Geography 2023
  • Figure 35. Global Antibiotic Resistance: by Disease USD Million (2025-2030)
  • Figure 36. Global Antibiotic Resistance: by Drug Class USD Million (2025-2030)
  • Figure 37. South America Antibiotic Resistance Share (%), by Country
  • Figure 38. Asia Pacific Antibiotic Resistance Share (%), by Country
  • Figure 39. Europe Antibiotic Resistance Share (%), by Country
  • Figure 40. MEA Antibiotic Resistance Share (%), by Country
  • Figure 41. North America Antibiotic Resistance Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Novartis AG (Switzerland)
  • Allergan (Ireland)
  • Melinta Therapeutics (United States)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline PLC (United Kingdom)
  • Merck & Co. Inc. (United States)
  • Sanofi SA (France)
  • Johnson & Johnson (United States)
  • Roche (Switzerland)
Additional players considered in the study are as follows:
Shionogi (Japan) , Lupin (India) , Sun Pharma (India) , Teva (Israel) , Mylan (United States)
Select User Access Type

Key Highlights of Report


Sep 2024 156 Pages 61 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antibiotic Resistance Market Quantitative research analysis
Global Antibiotic Resistance Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer Inc. (United States), Novartis AG (Switzerland), Allergan (Ireland), Melinta Therapeutics (United States), Novartis AG (Switzerland), GlaxoSmithKline PLC (United Kingdom), Merck & Co. Inc. (United States), Sanofi SA (France), Johnson & Johnson (United States) and Roche (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Latest Technological Advancements in Biotechnology Field" is seen as one of major influencing trends for Antibiotic Resistance Market during projected period 2023-2030.
The Antibiotic Resistance market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Antibiotic Resistance Market Report?

Have a Query? Click Here

Other Related Reports

BioPharma Buffers Comprehensive Study by Type (Phosphates, Acetates, TRIS, Others), Application (Research Institution, Pharmaceutical Industry, Others), Distribution Channel (Online, Offline), Packag...
$ 3450
Protein Labeling Comprehensive Study by Type (Reagents, Kits, Services), Application (Cell-based Assays, Fluorescence Microscopy, Immunological Techniques, Mass Spectrometry, Protein Microarray), Pro...
$ 3750
Umbilical Cord Blood Banking Comprehensive Study by Application (Cancers, Blood Disorders, Metabolic Disorders, Immune Disorders, Osteopetrosis, Others), Services (Sample Preservation, Analysis, Proc...
$ 3650
Protein Sequencing Comprehensive Study by Type (Reagents & Consumables, Instrument, Analysis Products, Protein Sequencing Service, Others), Application (Biotherapeutics, Genetic Engineering), End Use...
$ 3650
Nucleic Acid Isolation and Purification Comprehensive Study by Type (Kits, Reagents, Instruments), Application (Diagnostics, Drug Discovery and Development, Precision Medicine, Agriculture & Animal R...
$ 3750
Probiotics Tablets Comprehensive Study by Type (Digestive Support, Immune Support), Function (Regular, Preventive, Therapeutic), Ingredient (Bacteria, Yeast), End User (Child, Adult) Players and Regi...
$ 3500